ImmunoGen, Inc. (IMGN)

NASDAQ: IMGN · IEX Real-Time Price · USD
+0.30 (5.60%)
At close: Oct 5, 2022 4:00 PM
+0.04 (0.71%)
Pre-market: Oct 6, 2022 8:30 AM EDT

Total Valuation

ImmunoGen has a market cap or net worth of $1.23 billion. The enterprise value is $874.46 million.

Market Cap 1.23B
Enterprise Value 874.46M

Important Dates

The next earnings date is Thursday, October 27, 2022, before market open.

Estimated Earnings Date Oct 27, 2022
Ex-Dividend Date n/a

Share Statistics

ImmunoGen has 217.53 million shares outstanding. The number of shares has increased by 26.74% in one year.

Shares Outstanding 217.53M
Shares Change (YoY) +26.74%
Shares Change (QoQ) +0.03%
Owned by Insiders (%) 0.40%
Owned by Institutions (%) 92.08%
Float 171.44M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 13.77
Forward PS 9.07
PB Ratio 4.93
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 9.78
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.07.

Current Ratio 4.52
Quick Ratio 4.36
Debt / Equity 0.07
Debt / EBITDA n/a
Debt / FCF n/a

Financial Efficiency

Return on equity (ROE) is -67.00%.

Return on Equity (ROE) -67.00%
Return on Assets (ROA) -37.20%
Return on Capital (ROIC) n/a
Revenue Per Employee $843,792
Profits Per Employee -$1.52M
Employee Count 106
Asset Turnover 0.21
Inventory Turnover n/a


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -2.73% in the last 52 weeks. The beta is 0.90, so ImmunoGen's price volatility has been lower than the market average.

Beta (1Y) 0.90
52-Week Price Change -2.73%
50-Day Moving Average 5.34
200-Day Moving Average 4.80
Average Volume (30 Days) 2,941,342

Short Selling Information

The latest short interest is 12.14 million, so 5.58% of the outstanding shares have been sold short.

Short Interest 12.14M
Short % of Shares Out 5.58%
Short % of Float 7.08%
Short Ratio (days to cover) 3.85

Income Statement

In the last 12 months, ImmunoGen had revenue of $89.44 million and -160.68 million in losses. Earnings per share was -$0.59.

Revenue 89.44M
Gross Profit 89.44M
Operating Income -152.69M
Net Income -160.68M
EBITDA -158.82M
EBIT -160.68M
Earnings Per Share (EPS) -$0.59
Full Income Statement

Balance Sheet

The company has $373.87 million in cash and $17.12 million in debt, giving a net cash position of $356.75 million or $1.64 per share.

Cash & Cash Equivalents 373.87M
Total Debt 17.12M
Net Cash 356.75M
Net Cash Per Share $1.64
Book Value 249.83M
Book Value Per Share 1.15
Working Capital 306.85M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$186.31 million and capital expenditures -$1.01 million, giving a free cash flow of -$187.32 million.

Operating Cash Flow -186.31M
Capital Expenditures -1.01M
Free Cash Flow -187.32M
FCF Per Share n/a
Full Cash Flow Statement


Gross margin is 100.00%, with operating and profit margins of -170.72% and -179.64%.

Gross Margin 100.00%
Operating Margin -170.72%
Pretax Margin n/a
Profit Margin -179.64%
EBITDA Margin -177.57%
EBIT Margin -179.64%
FCF Margin -209.43%

Dividends & Yields

ImmunoGen does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield -13.05%
FCF Yield -15.21%
Dividend Growth (YoY) n/a
Payout Ratio n/a
Buyback Yield -26.74%
Shareholder Yield -26.74%
Dividend Details

Analyst Forecast

The average price target for ImmunoGen is $11.43, which is 101.94% higher than the current price. The consensus rating is "Buy".

Price Target $11.43
Price Target Difference 101.94%
Analyst Consensus Buy
Analyst Count 17
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a